🔬 Third-party verified peptides · Free Express Post over $200 CAD
Pantheon Peptides
Fat Loss3 cited studies

Retatrutide

Triple GIP / GLP-1 / glucagon receptor agonist — the next-generation incretin in Phase 3 trials.

SummaryMechanismDosingSafetyStudies
Research use only — not for human consumption.

What it is

Retatrutide is an investigational peptide with agonism at three metabolic receptors: GIP, GLP-1, and glucagon. It is being developed for sustainable weight reduction, glycemic control, and improved metabolic efficiency. Phase 2 data suggest weight-loss magnitude exceeding tirzepatide; Phase 3 TRIUMPH trials are ongoing.

Mechanism of action

Adds glucagon receptor agonism to the dual-incretin approach. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation, potentially compounding caloric-deficit effects from GLP-1 / GIP appetite suppression and insulin enhancement.

Half-life: ~6 days.

Evidence summary

Phase 2 (NEJM 2023) showed mean 24.2% weight loss at 48 weeks with 12 mg weekly. Subsequent body-composition and meta-analytic data (2025) support the magnitude of effect across BMI ranges.

Typical dosing protocols

Typical dose
2000–8000 mcg
Frequency
Once weekly
Cycle length
12 weeks
  • Starting dose: 2 mg subcutaneous weekly
  • Escalate by 2 mg every 4 weeks as tolerated
  • Maintenance: 4–12 mg weekly
  • Slow titration recommended due to additive GI side-effect profile

Side effects & safety

  • GI effects (nausea, vomiting, diarrhea) prominent during escalation
  • Elevations in heart rate reported at higher doses
  • Not yet FDA-approved — long-term safety under investigation

Cited studies

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
    PMID 37366315DOI 10.1056/NEJMoa2301972Read source ↗
  2. (2025). Effects of Retatrutide on body composition in people with type 2 diabetes. Diabetes, Obesity and Metabolism (NLM).
    Read source ↗
  3. (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity. JAMA Network Open (NLM).
    Read source ↗
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.